Open AccessThe Landmark Series: Management of Small Bowel Neuroendocrine Tumors
Author(s) -
Catherine Tran,
Scott K. Sherman,
James R. Howe
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-09566-4
Subject(s) - medicine , surgical oncology , neuroendocrine tumors , randomized controlled trial , somatostatin , surgical resection , targeted therapy , psychological intervention , overall survival , oncology , general surgery , cancer , psychiatry
Surgical resection is the foundation for treatment of small bowel neuroendocrine tumors (SBNETs). Guidelines for surgical management of SBNETs rely on retrospective data, which suggest that primary tumor resection and cytoreduction improve symptoms, prevent future complications, and lengthen survival. In advanced NETs, improvement in progression-free survival has been reported in large, randomized, controlled trials of various medical treatments, including somatostatin analogues, targeted therapy, and peptide receptor radionuclide therapy. This review discusses important studies influencing the management of SBNETs and the limitations of current evidence regarding surgical interventions for SBNETs.